Alzamend Neuro, Inc. (ALZN)

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-4.51	-9.95	-14.88	-12.36	-5.05
Depreciation & Amortization	0.05	0.05	0.02	0	-
Stock-Based Compensation	0.33	0.96	3.58	4.41	2.03
Other Operating Activities	0.01	0	-	0.01	0.45
Change in Accounts Payable	-2.29	0.05	1.71	0.69	-0.41
Change in Other Net Operating Assets	-0.15	0.62	0.64	0.63	0.26
Operating Cash Flow	-6.57	-8.27	-8.92	-6.61	-2.71
Capital Expenditures	-0.3	-0.15	-	-0.11	-
Other Investing Activities	-	-	-	-	0.1
Investing Cash Flow	-0.3	-0.15	-	-0.11	0.1
Short-Term Debt Issued	-	0.3	-	-	2.25
Total Debt Issued	-	0.3	-	-	2.25
Short-Term Debt Repaid	-	-	-	-0.06	-0
Total Debt Repaid	-	-	-	-0.06	-0
Net Debt Issued (Repaid)	-	0.3	-	-0.06	2.25
Issuance of Common Stock	2.7	1.25	0	18.91	2.2
Financing Cash Flow	10.44	3.65	0	18.85	4.45
Net Cash Flow	3.57	-4.76	-8.92	12.13	1.84
Free Cash Flow	-6.87	-8.42	-8.92	-6.72	-2.71
Free Cash Flow Per Share	-15.24	-111.97	-123.53	-101.83	-50.40
Levered Free Cash Flow	-5.19	-4.69	-4.33	-2.19	-0.41
Unlevered Free Cash Flow	-5.17	-4.68	-4.33	-2.16	-0.31
Change in Net Working Capital	2.44	-0.67	-1.36	-1.23	-0.38

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q